South Korea's Bridge Biotherapeutics has signed up to use the UK medtech firm's e-ILD software package in a phase 2 trial of BBT-877, its experimental therapy for serious lung disease idiopathic ...
The German pharma has already marketed its IPF drug Ofev (nintedanib) for almost five years but is looking to Bridge and its autotaxin inhibitor BBT-877 as a follow-up drug in patients with ...
In contrast, Bridge Biotherapeutics emphasizes that BBT-877 can effectively treat the decline in lung function. After acquiring BBT-877 from LigaChem Biosciences, the company is currently in the ...
In July 2024, Bridge Biotherapeutics announced that patient participant enrollment had been completed in the Phase II clinical study of BBT-877, a novel autotoxin (ATX) inhibitor for the treatment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback